Valuation
- Market cap
- 1,431,000
- Revenue TTM
- $580,000
- Net income TTM
- $-44,540,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -7,679.31%
- Debt to equity
- 0.00
Trading
- Volume
- 359,085
- Avg volume
- 12,707,749
- Day's range
- $0.22 – $0.24
- Shares out
- 5,411,000
- Stochastic %K
- 48%
- Beta
- 4.47
- Analysts
- Hold
- Price target
- —
Company profile
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rhe...
Show more
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 798 6700
- Website
- https://www.ernexatx.com
- Address
- 1035 Cambridge Street, Suite 18A, Cambridge, United States
Latest news
No headlines yet.
